Epidemiological Characteristics and Economic Burden of IgA Nephropathy—a Retrospective Study Using Multicenter Electronic Medical Records Data in China
Author(s)
feiyi xiao, PhD1, Xue Li, PhD2, Wudong Guo, PhD3, cui jun ge, master4, Rui Li5, Peimeng Wang, master6, Xin GAO, master7.
1China Beijing, China National Health Development Research Center, Bei Jing, China, 2National Health Development Research Center, Beijing, China, 3China National Health Development Research Center, Bei Jing, China, 4DALIAN MEDICAL UNIVERSITY, Dalian, China, 5lir2018@lzu.edu.cn, China, 6China National Health Development Research Center, Beijing, China, 7Health Economics Research Institute, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
1China Beijing, China National Health Development Research Center, Bei Jing, China, 2National Health Development Research Center, Beijing, China, 3China National Health Development Research Center, Bei Jing, China, 4DALIAN MEDICAL UNIVERSITY, Dalian, China, 5lir2018@lzu.edu.cn, China, 6China National Health Development Research Center, Beijing, China, 7Health Economics Research Institute, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
OBJECTIVES: To analyze the epidemiological characteristics and economic burden of patient with IgAN in China using multi-center electronic medical records.IgA nephropathy (IgAN) is a major cause of chronic kidney disease (CKD) . When IgAN leads to persistent structural or functional renal abnormalities over 3 months, it can be identified as CKD. 20%-40% of IgAN patients progressing to CKD stage 5 within 10-20 years. Large-scale epidemiological and economic burden data remain scarce.
METHODS: A retrospective cohort included IgAN patients diagnosed by renal biopsy from hospitals in Tianjin, Wuhan,Jinan,and Nanjing (2015-2025). CKD severity (stages 1-5) was classified based on eGFR baseline according to Kidney Disease: Improving Global Outcomes(KDIGO) guidelines. Demographics, clinical manifestations, pathological features, and direct medical costs were analyzed.
RESULTS: 13,193 patients were identified, with 6,227 meeting inclusion/exclusion criteria. Of all patients, 3033 were males(48.7%), with mean diagnosis age of 41.1(14.1) years (47.6% aged 20-40). Hematuria (48.1%) and proteinuria (50.7%) were the top two commnon symptoms identified. In regarding to the severity of IgAN on the first diagnosis, 5.9%, 42.6% and 51.2% patients were at CKD 1-2, CKD 3-4 and CKD 5 respectively. Pathological patterns included mesangial hyperplasia (95.3%), endothelial hyperplasia (79.4%), and segmental sclerosis (44.1%). The average annual total medical costs were $4,724. Median costs were different with CKD stages, with $3,759 (CKD 1-2), $8,182 (CKD 3-4), and $5,237 (CKD 5) respectively. Drug/treatment costs were dominating in the total costs at CKD 1-4, while costs of dialysis shifted structure of total cost for patients at CKD 5. CKD 5 patients had higher resource utilization, with 39.3 annual outpatient visits and 1.12 hospitalizations, compared to CKD 1-4 patients (1.45 outpatient visits, 0.98 hospitalizations).
CONCLUSIONS: Chinese IgAN shows a young-onset trend, with nearly half diagnosed at CKD 5. Economic burden escalates with disease severity, underscoring the need for early intervention and optimized resource allocation.
METHODS: A retrospective cohort included IgAN patients diagnosed by renal biopsy from hospitals in Tianjin, Wuhan,Jinan,and Nanjing (2015-2025). CKD severity (stages 1-5) was classified based on eGFR baseline according to Kidney Disease: Improving Global Outcomes(KDIGO) guidelines. Demographics, clinical manifestations, pathological features, and direct medical costs were analyzed.
RESULTS: 13,193 patients were identified, with 6,227 meeting inclusion/exclusion criteria. Of all patients, 3033 were males(48.7%), with mean diagnosis age of 41.1(14.1) years (47.6% aged 20-40). Hematuria (48.1%) and proteinuria (50.7%) were the top two commnon symptoms identified. In regarding to the severity of IgAN on the first diagnosis, 5.9%, 42.6% and 51.2% patients were at CKD 1-2, CKD 3-4 and CKD 5 respectively. Pathological patterns included mesangial hyperplasia (95.3%), endothelial hyperplasia (79.4%), and segmental sclerosis (44.1%). The average annual total medical costs were $4,724. Median costs were different with CKD stages, with $3,759 (CKD 1-2), $8,182 (CKD 3-4), and $5,237 (CKD 5) respectively. Drug/treatment costs were dominating in the total costs at CKD 1-4, while costs of dialysis shifted structure of total cost for patients at CKD 5. CKD 5 patients had higher resource utilization, with 39.3 annual outpatient visits and 1.12 hospitalizations, compared to CKD 1-4 patients (1.45 outpatient visits, 0.98 hospitalizations).
CONCLUSIONS: Chinese IgAN shows a young-onset trend, with nearly half diagnosed at CKD 5. Economic burden escalates with disease severity, underscoring the need for early intervention and optimized resource allocation.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH75
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), Urinary/Kidney Disorders